Trial · NCT04545554
Adverse events216
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 216
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Ocular hyperaemia | Eye disorders | Cohort 1: Romosozumab Dose A (12 to < 18 Years of Age) | 0 | 4 | |
| other | Ocular hyperaemia | Eye disorders | Cohort 2: Romosozumab Dose A (5 to < 12 Years of Age) | 0 | 4 | |
| other | Ocular hyperaemia | Eye disorders | Cohort 3: Romosozumab Dose B (12 to < 18 Years of Age) | 0 | 4 | |
| other | Ocular hyperaemia | Eye disorders | Cohort 4: Romosozumab Dose B (5 to < 12 Years of Age) | 1 | 5 | |
| other | Ocular hyperaemia | Eye disorders | Cohort 5: Romosozumab Dose C (12 to < 18 Years of Age) | 0 | 4 | |
| other | Ocular hyperaemia | Eye disorders | Cohort 6: Romosozumab Dose C (5 to < 12 Years of Age) | 0 | 4 | |
| other | Abdominal pain | Gastrointestinal disorders | Cohort 1: Romosozumab Dose A (12 to < 18 Years of Age) | 0 | 4 | |
| other | Abdominal pain | Gastrointestinal disorders | Cohort 2: Romosozumab Dose A (5 to < 12 Years of Age) | 0 | 4 | |
| other | Abdominal pain | Gastrointestinal disorders | Cohort 3: Romosozumab Dose B (12 to < 18 Years of Age) | 0 | 4 | |
| other | Abdominal pain | Gastrointestinal disorders | Cohort 4: Romosozumab Dose B (5 to < 12 Years of Age) | 0 | 5 | |
| other | Abdominal pain | Gastrointestinal disorders | Cohort 5: Romosozumab Dose C (12 to < 18 Years of Age) | 0 | 4 | |
| other | Abdominal pain | Gastrointestinal disorders | Cohort 6: Romosozumab Dose C (5 to < 12 Years of Age) | 1 | 4 | |
| other | Abnormal faeces | Gastrointestinal disorders | Cohort 1: Romosozumab Dose A (12 to < 18 Years of Age) | 0 | 4 | |
| other | Abnormal faeces | Gastrointestinal disorders | Cohort 2: Romosozumab Dose A (5 to < 12 Years of Age) | 0 | 4 | |
| other | Abnormal faeces | Gastrointestinal disorders | Cohort 3: Romosozumab Dose B (12 to < 18 Years of Age) | 0 | 4 | |
| other | Abnormal faeces | Gastrointestinal disorders | Cohort 4: Romosozumab Dose B (5 to < 12 Years of Age) | 1 | 5 | |
| other | Abnormal faeces | Gastrointestinal disorders | Cohort 5: Romosozumab Dose C (12 to < 18 Years of Age) | 0 | 4 | |
| other | Abnormal faeces | Gastrointestinal disorders | Cohort 6: Romosozumab Dose C (5 to < 12 Years of Age) | 0 | 4 | |
| other | Constipation | Gastrointestinal disorders | Cohort 1: Romosozumab Dose A (12 to < 18 Years of Age) | 0 | 4 | |
| other | Constipation | Gastrointestinal disorders | Cohort 2: Romosozumab Dose A (5 to < 12 Years of Age) | 0 | 4 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04545554/events